EUVIMEDEUVIMED entdecken
Kohortenstudie

Efficacy and safety of Jinhua Qinggan Granule, a compound Chinese herbal medicine, in oldest-old patients with COVID-19: A retrospective cohort study

Lei-Lei Chen, Wen-Jing Zhai, Juan Bao, Zheng-Hao Yu, Tian-Yi Zhang, Xue-Chun Lu, Lin Liu, Li Chen, Su-Yang Wang, Jing Hu, Xin Gao, Qi Zhang und 2 weitere

Journal of Integrative Medicine · 2025

DOI: 10.1016/j.joim.2025.10.005 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Integrative Medicine, 2025. Verfasst von Lei-Lei Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Medical Supplies Center of Chinese PLA General Hospital, Beijing 100853, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Limited data are available on the use of antiviral drugs among oldest-old patients. This study investigates the effect of Jinhua Qinggan Granule (JHQG), a compound Chinese herbal medicine, on the efficacy and safety of nirmatrelvir/ritonavir in oldest-old patients with coronavirus disease 2019 (COVID-19). METHODS: A total of 180 oldest-old patients with confirmed COVID-19 at the Chinese PLA General Hospital from July 2023 to July 2024 were enrolled in this retrospective cohort study and were divided into a monotherapy group (nirmatrelvir/ritonavir, n = 89) and a combination therapy group (nirmatrelvir/ritonavir plus JHQG, n = 91) according to the treatments received. The primary outcome was the cumulative rate of nucleic acid negative conversion (NANC) on the fifth day after initiation of treatment. The secondary outcomes included the rates of improvement in the main symptoms, the duration of fever, and variations in clinical laboratory indices. The safety outcomes included the incidence of adverse drug reactions (ADRs) and indicators of liver and kidney function. RESULTS: Among the 180 oldest-old patients participating in the study, the median (P25, P75) age was 93.0 (86.0, 96.0) years, and 94.44% were male. The rate of NANC within five days was significantly higher in the combination therapy group than in the monotherapy group (80.22% vs 66.29%, P = 0.035). The addition of JHQG was significantly associated with NANC within five days in the multivariable analysis (odds ratio [OR] = 2.216; 95% confidence interval [CI]: 1.066-4.607; P = 0.033). Furthermore, compared with nirmatrelvir/ritonavir alone, combination therapy had better effects on the recovery rates of various symptoms, including fever, cough, expectoration, and all respiratory symptoms, as well as the time to recovery from fever (P 0.05). CONCLUSION: Among oldest-old patients with COVID-19, the addition of JHQG to nirmatrelvir/ritonavir significantly improves early clinical recovery without increasing safety concerns. Please cite this article as: Chen LL, Zhai WJ, Bao J, Yu ZH, Zhang TY, Lu XC, Liu L, Chen L, Wang SY, Hu J, Gao X, Zhang Q, Xu GG, Xin HL. Efficacy and safety of Jinhua Qinggan Granule, a compound Chinese herbal medicine, in oldest-old patients with COVID-19: A retrospective cohort study. J Integr Med. 2026; 24(4):566-572.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalCOVID-19 Drug TreatmentAntiviral AgentsHumansRetrospective StudiesAged, 80 and overMaleRitonavirFemaleSARS-CoV-2Drug Therapy, CombinationCOVID-19Treatment Outcome

Stichwörter der Autor:innen

COVID-19Cohort studyJinhua Qinggan GranuleNirmatrelvir/ritonavirOldest-old patients

Substanzen

Drugs, Chinese HerbalRitonavirAntiviral Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Medical Supplies Center of Chinese PLA General Hospital, Beijing 100853, China.
  • Department of Pharmacy, Jingdong Medical Area of Chinese PLA General Hospital, Beijing 101199, China.
  • Health Management Institute, the Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China.
  • Department of Medical Innovation and Research, Chinese PLA General Hospital, Beijing 100853, China.
  • Department of Geriatric Hematology, the Second Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
  • Department of Respiratory and Critical Care Medicine, the Second Medical Center, Chinese PLA General Hospital, Beijing 100853, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Chen, L. L., Zhai, W. J., Bao, J., Yu, Z. H., Zhang, T. Y., Lu, X. C., Liu, L., Chen, L., Wang, S. Y., Hu, J., Gao, X., Zhang, Q., Xu, G. G., & Xin, H. L. (2025). Efficacy and safety of Jinhua Qinggan Granule, a compound Chinese herbal medicine, in oldest-old patients with COVID-19: A retrospective cohort study. Journal of Integrative Medicine. https://doi.org/10.1016/j.joim.2025.10.005

Vancouver

Chen LL, Zhai WJ, Bao J, Yu ZH, Zhang TY, Lu XC, et al. Efficacy and safety of Jinhua Qinggan Granule, a compound Chinese herbal medicine, in oldest-old patients with COVID-19: A retrospective cohort study. Journal of Integrative Medicine. 2025. doi:10.1016/j.joim.2025.10.005

BibTeX
@article{Chen2025,
  author = {Chen, Lei-Lei and Zhai, Wen-Jing and Bao, Juan and Yu, Zheng-Hao and Zhang, Tian-Yi and Lu, Xue-Chun and Liu, Lin and Chen, Li and Wang, Su-Yang and Hu, Jing and Gao, Xin and Zhang, Qi and Xu, Guo-Gang and Xin, Hai-Li},
  title = {Efficacy and safety of Jinhua Qinggan Granule, a compound Chinese herbal medicine, in oldest-old patients with COVID-19: A retrospective cohort study},
  journal = {Journal of Integrative Medicine},
  year = {2025},
  doi = {10.1016/j.joim.2025.10.005}
}
Kostenlos starten →